Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient.
Mani
Laila-Yasmin
LY
Nseir
Ghaleb
G
Venetz
Jean-Pierre
JP
Pascual
Manuel
M
D000328:Adult; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D005919:Glomerular Filtration Rate; D006801:Humans; D017674:Hypophosphatemia / Q000139:chemically induced*; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects*; D019520:Living Donors; D008320:Maltose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010710:Phosphates / Q000097:blood; D007690:Polycystic Kidney Diseases / Q000601:surgery; D012016:Reference Values; D014184:Transplantation, Homologous
D005290:Ferric Compounds; D010710:Phosphates; C522335:ferric carboxymaltose; D008320:Maltose